Patients more than 18 years of age who have previously received antiretroviral regimens Tenofovir/Emtricitabine/Efavirenz for more than or equal to 6 months and have an HIV-1 RNA viral load of less than 20 copies/ml within 6 months before the study. HIV, Tenofovir/ Emtricitabine/Dolutegravir, Tenofovir/ Emtricitabine/ Rilpivirine, weight gain, metabolic syndrome
Conditions
Interventions
Tenofovir/ Emtricitabine/Dolutegravir is an oral medication.,Tenofovir/ Emtricitabine/ Rilpivirine is an oral medicaton.
Active Comparator Drug,Active Comparator Drug
Tenofovir/ Emtricitabine/Dolutegravir,Tenofovir/ Emtricitabine/ Rilpivirine
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients more than 18 years of age who have previously received antiretroviral regimens Tenofovir/Emtricitabine/Efavirenz for more than or equal to 6 months and have an HIV-1 RNA viral load of less than 20 copies/ml within 6 months before the study.
Exclusion criteria
Exclusion criteria: 1. Infected with HIV 2 RNA, 2. Evidence that one of the antiretroviral drug resistance genes is found, 3. Drug interactions such as proton pump inhibitors, H2 receptor antagonists, rifampicin, and anticonvulsants, 4. Being pregnant or breastfeeding, 5. The renal function calculated from the Cockcroft Gault equation is less than 60 mL/min, 6. Have a psychiatric illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Virological suppression at 6 months after end of the intervention HIV viral load | — |
Secondary
| Measure | Time frame |
|---|---|
| the changes in blood lipids, blood sugar, body weight, subcutaneous fat mass, and the waist circumference at 6 months after end of the intervention Laboratory test | — |
Countries
Thailand
Contacts
Public ContactRattagan Kajeekul
Ministry of Health
Outcome results
None listed